DiaMedica Therapeutics (DMAC) Gains from Investment Securities (2018)
DiaMedica Therapeutics' (DMAC) quarterly Gains from Investment Securities came in at $39000.0 in Q1 2018.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Gains from Investment Securities (2018) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Gains from Investment Securities for 1 consecutive years, with $39000.0 the latest figure, recorded in Q1 2018.
- For the quarter ending Q1 2018, Gains from Investment Securities changed N/A year-over-year to $39000.0; the trailing twelve-month figure through Dec 2018 stood at $39000.0 (changed N/A YoY), and the FY2018 full-year result was $39000.0, up 533.33% from the prior year.
- Gains from Investment Securities was little changed at $39000.0 in Q1 2018 per DMAC's latest filing.
- Across five years, Gains from Investment Securities topped out at $39000.0 in Q1 2018 and bottomed at $39000.0 in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.13 Bn | 193.14 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.53 Bn | 176.35 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.46 Bn | 123.61 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.89 Bn | 73.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.12 Bn | 55.94 Bn | 1.37 Bn |
| 6 | Moderna | 53.31 Bn | 48.17 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.36 Bn | 30.05 Bn | 992.69 Mn |
| 8 | Biogen | 31.72 Bn | 30.43 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.32 Bn | 29.32 Bn | 1.16 Mn |
| 10 | DiaMedica Therapeutics | 346.00 Mn | 346.00 Mn | - |